Keros Therapeutics, Inc.'s stock plummets 75% due to safety concerns in Phase 2 trial, but partnership with Takeda may offer ...

Postmarketing data on obeticholic acid (Ocaliva) identified a risk for serious liver injury in primary biliary cholangitis ...

The FDA has placed a hold on all clinical studies of vaccines for respiratory syncytial virus in infants due to safety concerns following a trial involving two mRNA-based vaccine candidates from ...

An investigation published in The BMJ raises new concerns over the landmark clinical trial (PLATO) that was used to gain ...

Intercept Pharmaceuticals' liver disease drug is being observed for injury to the organ in patients without severe scarring, ...

CIDRAP: Recombinant Pertussis Vaccine May Protect Teens For At Least 5 Years Researchers report that immunity against pertussis (whooping cough) was sustained 5 years after receipt of a ...

An emergency ban on hormones used to suppress puberty in transgender young people in the U.K. has been extended indefinitely, the government said.

Petrovax has announced positive results stemming from the Long-CoV-III-21 trial, which tested the efficacy of bovhyaluronidase azoximer (Longidaza) in patients with long-term COVID-19 pulmonary ...

OSF Cancer Institute is one of the chosen few participants in an exciting new cancer treatment trial program. The founder of ...

Nonwhite adults with mild cognitive impairment (MCI) are more likely to live in areas with higher pollution, according to a study.

Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who ...

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies ...